Home > Research Description > MS Imaging & MS Developments

MS Imaging & MS Developments

Fundamental & Technological Developments for Clinics

Logo EU Region Nord {JPEG}

The Molecular MS Imaging Technology for Health

MALDI Imaging Team (MIT) was created in 2004, after Pr. I. Fournier obtained a National Starting Grant (ACI young). Initially, MALDI MS Imaging was started in the lab in 2002. Since its creation two main research directions were pursued in the group i.e. technological developments and biological application transversally to the two other axes of PRISM in REGENESIS, MIMIC, GLIOMIC and OVC.

Technological developments are focused on molecular mass spectrometry imaging (MSI) improvements on tissue preparation whatever is nature (fresh frozen or Formalin Fixed paraffin embedded (FFPE)) and biomolecules identification keeping the spatial localization. Novel MALDI matrices (ionic matrices), matrix deposition methods (spray, automatic spotting with piezo head), on tissue microdigestion, on tissue peptides derivatization, unlocking FFPE tissue, bioinformatics (novel imaging software, MITICS, Principal-component analysis-symbolic discriminant analysis method, PCA-SDA), novel pre-spotted MALDI plates with ionic matrix, as well as targeted-MSI based on Tag-mass developments are one of the major improvement performed by MIT since this last 10 years. MIT now emphases four main projects for MALDI MSI improvement consisting 1) on tissue microproteomic for high throughput and high number proteins identification, 2) on tissue protein quantification, and 3) on tissue protein structure analyses, 4) correlated transciptome to proteome. All of these developments are included in two major projects so called QUEST-MSI and ATAMS. The second main technological developments of PRISM is the SPIDERMASS project for in vivo diagnosis based on mass spectrometry.

QUEST-MSI project aims to set up a novel analytical platform, for spatially-resolved, quantitative, and highly-sensitive analysis of proteins. A new workflow based on spatially resolved protein extraction followed by in-solution processing will allow high confidence identification of a large number of proteins, quantification of identified proteins, and the ability to reconstruct quantitative images of spatial abundance for the identified proteins.

ATAMS project aims consists in the development of a multiplex, highly sensitive technology allowing to detected biomarkers in fluids at atmol range for early diagnoses of several clinical pathologies. ATAMS (project will thus be based on the originally US patent developed by FABMS ) with a novel Tag synthesis created on click chemistry for a more rapid and cheaper production for kits production. Based on this novel generation of UTP-tagged mass, ATAMS can be used in clinics either for biomarkers titration in fluids or for pathogens identification.

MALDI orbitrap Photo 2